(Q46549438)

English

Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation

scientific article published in March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

1 reference

Europe PubMed Central

Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

0 references

author name string

P M Llorca

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

H Miadi-Fargier

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

C Lançon

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

G Jasso Mosqueda

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

F Casadebaig

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

A Philippe

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

P Guillon

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

A Mehnert

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

L F Omnès

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

A Chicoye

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

I Durand-Zaleski

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

number of pages

12

1 reference

based on heuristic

inferred from page(s)

L'Encephale: revue de psychiatrie clinique biologique et therapeutique

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

31

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

235-246

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

Cost Analysis of the Treatment of Schizophrenia in the UK

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

Long-term depot antipsychotics. A risk-benefit assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

Olanzapine. A pharmacoeconomic review of its use in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

Prospective study of course of illness in schizophrenia: Part III. Treatment and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

Compliance with depot antipsychotic medication by patients attending outpatient clinics

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

Some aspects of the cost of schizophrenia in France.

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

Depot neuroleptics in relapse prevention: advantages and disadvantages.

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2805%2982390-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0013-7006(05)82390-5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/15959450

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46549438&oldid=2117540596"